Compare Flex Ltd (FLEX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flex Ltd vs TG Therapeutics Inc — how do they compare? Flex Ltd trades at $117.2 (market cap $42.40B), while TG Therapeutics Inc trades at $53.34 (market cap $8.16B). The key difference: Flex Ltd is far larger — about 5.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Flex Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 3 Days and TG Therapeutics Inc for 15 Days on average.
| FLEX | TGTX | |
|---|---|---|
Market Cap | $42.40B | $8.16B |
Volume | 2,642,359 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $162.07 | $59.06 |
52-Week Low | $54.51 | $26.94 |
Typical Hold Time | 3 Days | 15 Days |
Enterprise Value | $45.49B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flex Ltd
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
